Document is current
Any future updates will be listed below
-
Authors
Liu, Dingwen
Tang, Lian
Xiong, Wei
Xu, Ran
Zhou, Qing
Xu, Genming
Li, Zhen
Tang, Wei
Feng, Jinru
Zeng, Xiaowei
Liu, Jinlei
Li, Chao
Chen, Lei
Wang, Long https://orcid.org/0000-0003-4583-2428
-
Funding
Funding for this research was provided by:
the Clinical Collaboration Program for Complex and Refractory Diseases Integrating Chinese and Western Medicine—Prostate Cancer (ZDYN-2024-A-084)
the Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University (No. BJ202504)
the Furong Scholars Program of Hunan Province
- License Information
-
More Information
Article History
Received: 12 February 2026
Revised: 24 July 2026
Accepted: 26 July 2026
First Online: 7 August 2026
Declarations
Ethics approval and consent to participate: The study protocol was approved by the Ethics Committee of the Third Xiangya Hospital, Central South University, in January 2024 (Approval No. Expedited review 24003). All procedures were performed in accordance with the principles of the 1975 Declaration of Helsinki. The trial is registered with the Chinese Clinical Trial Registry (ChiCTR2400081119; ). Informative consent was obtained from all individual participants included in the study.
Consent for publication: Not applicable.
Competing interests: Lian Tang, Genming Xu, Wei Tang, Jinru Feng, Xiaowei Zeng, and Jinlei Liu are current employees of Yearth Biotechnology Co., Ltd. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
